The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AGEN | +48.81% | -92.88% | -41.05% | -100% |
| S&P | +18.55% | +83.81% | +12.95% | +386% |
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $30.24M | 20.4% |
| Gross Profit | $26.56M | 22.9% |
| Gross Margin | 87.85% | 1.8% |
| Market Cap | $122.68M | 3.8% |
| Market Cap / Employee | $388.22K | 0.0% |
| Employees | 316 | 0.0% |
| Net Income | $63.91M | 195.1% |
| EBITDA | -$1,832.00K | 93.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.46M | -92.3% |
| Accounts Receivable | $6.26M | 2925.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $226.11M | -4.9% |
| Short Term Debt | $114.84M | -37.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.89% | 64.4% |
| Return On Invested Capital | 67.41% | -1050.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$14,737.00K | 72.4% |
| Operating Free Cash Flow | -$14,737.00K | 72.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.20 | -0.11 | -0.36 | -0.33 | -19.85% |
| Price to Sales | 0.60 | 0.37 | 1.26 | 1.18 | 60.87% |
| Price to Tangible Book Value | -0.19 | -0.10 | -0.33 | -0.30 | -18.29% |
| Enterprise Value to EBITDA | -19.11 | -44.99 | -39.67 | -249.59 | 1356.56% |
| Total Debt | $431.35M | $416.94M | $402.76M | $340.94M | -18.94% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
